{"ticker": {"uuid": "89c37fbb-3f4a-4976-a176-9502b7c64bc5", "symbol": "XFOR", "name": "X4 Pharmaceuticals Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "X4 Pharmaceuticals (XFOR) Proxy filing Summary", "summary": "X4 Pharmaceuticals has released a proxy filing summary detailing the upcoming annual meeting on May 11, 2026. Stockholders will vote on director elections, auditor ratification, an equity plan amendment, and executive compensation. The Board recommends approving all proposals, an", "url": "https://quartr.com/events/x4-pharmaceuticals-xfor-proxy-filing_onpZyYpT", "source_name": "Quartr", "published_at": "2026-07-13T14:41:18", "published_display": "13 Jul 2026 14:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "X4 Pharmaceuticals (XFOR) Q4 2025 earnings summary", "summary": "X4 Pharmaceuticals (XFOR) reported its Q4 2025 earnings, highlighting that enrollment for its 4WARD Phase 3 chronic neutropenia trial is on track for completion in Q3 2026 and expects final EU approval for mavorixafor for WHIM syndrome in Q2 2026. The company posted net product s", "url": "https://quartr.com/events/x4-pharmaceuticals-inc-xfor-q4-2025_onpZBAiR", "source_name": "Quartr", "published_at": "2026-07-13T13:12:21", "published_display": "13 Jul 2026 13:12", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "X4 Pharmaceuticals (XFOR) Corporate presentation Summary", "summary": "X4 Pharmaceuticals is focused on developing mavorixafor for chronic neutropenia, with its Phase 3 4WARD study fully enrolling by Q3 2026. The company secured $240M, reduced its workforce by 50%, and expects its cash runway to last through 2028. Mavorixafor, already approved for W", "url": "https://quartr.com/events/x4-pharmaceuticals-inc-xfor-corporate-presentation_onpZys2t", "source_name": "Quartr", "published_at": "2026-07-13T00:41:18", "published_display": "13 Jul 2026 00:41", "sentiment": "positive", "sentiment_pct": 77, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "X4 Pharmaceuticals (XFOR) Registration filing Summary", "summary": "X4 Pharmaceuticals (XFOR) has filed a registration summary, detailing its focus on developing therapeutics for rare hematology diseases, primarily with its main asset, mavorixafor. The company provided financial metrics as of March 31, 2026, including outstanding shares and per-s", "url": "https://quartr.com/events/x4-pharmaceuticals-inc-xfor-registration-filing_onpZy5um", "source_name": "Quartr", "published_at": "2026-07-13T00:41:18", "published_display": "13 Jul 2026 00:41", "sentiment": "positive", "sentiment_pct": 59, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "X4 Pharmaceuticals (XFOR) Q1 2026 earnings summary", "summary": "X4 Pharmaceuticals reported a Q1 2026 net loss of $20.2 million, a significant drop from Q1 2025's net income, primarily due to lower license revenue despite increased product revenue from XOLREMDI. The company is focused on commercializing XOLREMDI, recently approved in the EU, ", "url": "https://quartr.com/events/x4-pharmaceuticals-inc-xfor-q1-2026_onpZyscr", "source_name": "Quartr", "published_at": "2026-07-13T00:41:18", "published_display": "13 Jul 2026 00:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wells Fargo initiates X4 Pharmaceuticals stock coverage with overweight rating by Investing.com", "summary": "Wells Fargo has initiated coverage on X4 Pharmaceuticals (NASDAQ:XFOR) with an overweight rating and an $11.00 price target, citing the potential of its drug candidate mavorixafor for chronic neutropenia. A Phase 3 trial readout is anticipated in the second half of 2027, with the", "url": "https://ca.investing.com/news/stock-market-news/wells-fargo-initiates-x4-pharmaceuticals-stock-coverage-with-overweight-rating-93CH-4728859", "source_name": "Investing.com Canada", "published_at": "2026-07-10T10:39:45", "published_display": "10 Jul 2026 10:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "X4 Pharmaceuticals stock focuses on rare disease pipeline after Nasdaq listing", "summary": "X4 Pharmaceuticals, trading on Nasdaq as XFOR, is a clinical-stage biopharmaceutical company focused on developing small-molecule therapies for rare primary immunodeficiency and related disorders. Its strategy centers on niche medical needs and orphan drug designation, providing ", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/x4-pharmaceuticals-stock-focuses-on-rare-disease-pipeline-after-nasdaq/69733172", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-09T15:07:04", "published_display": "09 Jul 2026 15:07", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "X4 Pharmaceuticals gives new employees 750,000 stock options", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQbFBSMGtSMUlTYWVKQktEWVEydGVyMXNZak1FRHNSSFlKRGZCbU9lUGZMWVQzemJCNFZNSTVBamJLQzNjX29RM09aLTlGbHFTNmhENDBBMEIwNWFId2lYbk83V1Nsc0RFYWFKWDhyaU5jX2JiSzlBZFVoSHJQVGRYRXVNRWlkdkhwNm1HQ3p2cTJhUlc0Nk8xb1JsNGN4NGVPN1llaDI4alJkbm9ObG85bS01Rk1YZWRQTUtjN1VTZw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-07T20:30:00+00:00", "published_display": "07 Jul 2026 20:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "summary": "X4 Pharmaceuticals (Nasdaq: XFOR) has granted 750,000 stock options to new employees as inducement awards under its 2019 Inducement Equity Incentive Plan, effective July 6, 2026. The options have an exercise price of $4.03 per share, matching the closing price on the grant date, ", "url": "https://www.stocktitan.net/news/XFOR/x4-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-971eku1v7qwh.html", "source_name": "Stock Titan", "published_at": "2026-07-07T20:10:01", "published_display": "07 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of X4 Pharmaceuticals, Inc. \u2013 NASDAQ:XFOR", "summary": "This article provides the \"Price to earnings forward\" metric for X4 Pharmaceuticals, Inc. (NASDAQ: XFOR). The information, sourced from TradingView and FactSet, is presented without specific numerical values but indicates the availability of financial data for the company. The co", "url": "https://www.tradingview.com/symbols/NASDAQ-XFOR/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T12:40:01", "published_display": "06 Jul 2026 12:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XFOR Stock News Today | Earnings, Events & Price Alerts", "summary": "This article provides recent news and event updates for X4 Pharmaceuticals (XFOR). Key highlights include recent grants of inducement awards to new employees, the appointment of Kelly Gold to the Board of Directors, and the completion of EU approval for XOLREMDI\u00ae, along with posi", "url": "https://intellectia.ai/en/stock/XFOR/news", "source_name": "Intellectia AI", "published_at": "2026-07-06T11:11:03", "published_display": "06 Jul 2026 11:11", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of X4 Pharmaceuticals, Inc. \u2013 NASDAQ:XFOR", "summary": "This article focuses on the \"Price to sales forward\" financial metric for X4 Pharmaceuticals, Inc. (NASDAQ: XFOR). It appears to be a stub or a section within a larger financial data platform, providing a snapshot of this specific valuation ratio for the company without further d", "url": "https://www.tradingview.com/symbols/NASDAQ-XFOR/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T02:09:33", "published_display": "05 Jul 2026 02:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of X4 Pharmaceuticals, Inc. \u2013 NASDAQ:XFOR", "summary": "This article focuses on the enterprise value to EBITDA forward for X4 Pharmaceuticals, Inc. (NASDAQ: XFOR). The content, likely financial data, is presented through TradingView, a financial platform. It indicates that the market is closed and no trades have occurred for the speci", "url": "https://www.tradingview.com/symbols/NASDAQ-XFOR/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-03T11:10:30", "published_display": "03 Jul 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "X4 Pharmaceuticals Appoints Kelly Gold, Experienced Chief Financial Officer, to its Board of Directors", "summary": "X4 Pharmaceuticals (Nasdaq: XFOR) has appointed Kelly Gold, an experienced Chief Financial Officer, to its Board of Directors, effective July 1, 2026. Ms. Gold brings significant financial leadership and capital markets expertise, and will serve as an independent director and mem", "url": "https://www.sahmcapital.com/news/content/x4-pharmaceuticals-appoints-kelly-gold-experienced-chief-financial-officer-to-its-board-of-directors-2026-07-01", "source_name": "Sahm", "published_at": "2026-07-02T22:40:01", "published_display": "02 Jul 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kelly Gold joins X4 Pharmaceuticals (Nasdaq: XFOR) board and Audit Committee", "summary": "X4 Pharmaceuticals (Nasdaq: XFOR) has appointed Kelly Gold as a Class II independent director to its Board, effective July 1, 2026. This appointment expands the board from five to six members, and Gold will also serve on the Audit Committee. Gold brings extensive financial leader", "url": "https://www.stocktitan.net/sec-filings/XFOR/8-k-x4-pharmaceuticals-inc-reports-material-event-f7da0be9f79e.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:40:40", "published_display": "01 Jul 2026 20:40", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "X4 Pharmaceuticals (XFOR) director Gold Kelly files initial Form 3 ownership", "summary": "X4 Pharmaceuticals director Gold Kelly has filed an initial Form 3, indicating her beneficial ownership status as a director. This filing serves as a baseline disclosure and does not report any insider stock transactions or derivative securities. The Form 3 details Kelly's positi", "url": "https://www.stocktitan.net/sec-filings/XFOR/form-3-x4-pharmaceuticals-inc-initial-statement-of-beneficial-ownersh-0433155755f8.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:40:40", "published_display": "01 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 X4 Pharmaceuticals Inc For: 1 July By Investing.com", "summary": "This article from Investing.com reports the filing of Form 4 for X4 Pharmaceuticals Inc., dated July 1st. Form 4 is a document that must be filed with the SEC whenever a company insider (such as an officer, director, or 10%+ shareholder) trades the company's stock. The article pr", "url": "https://ca.investing.com/news/stock-market-news/form-4-x4-pharmaceuticals-inc-for-1-july-93CH-4717027", "source_name": "Investing.com Canada", "published_at": "2026-07-01T20:40:40", "published_display": "01 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director Kelly Gold granted 110,000 X4 Pharmaceuticals (XFOR) stock options at $4.085", "summary": "X4 Pharmaceuticals director Kelly Gold was granted 110,000 stock options with an exercise price of $4.085 per share, expiring on July 1, 2036. These options vest fully on the one-year anniversary of the grant date, provided Gold continues to provide services to the company. Follo", "url": "https://www.stocktitan.net/sec-filings/XFOR/form-4-x4-pharmaceuticals-inc-insider-trading-activity-58ca91bac4e3.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:40:40", "published_display": "01 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "X4 Pharmaceuticals (XFOR) CFO sells 8,543 shares to cover RSU tax", "summary": "X4 Pharmaceuticals' CFO, David Kirske, sold 8,543 shares of common stock at a weighted average price of $4.2641 per share. This sale was conducted to satisfy a personal income tax obligation arising from the settlement of a restricted stock unit (RSU) award. Following the transac", "url": "https://www.stocktitan.net/sec-filings/XFOR/form-4-x4-pharmaceuticals-inc-insider-trading-activity-35222244f043.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:40:40", "published_display": "01 Jul 2026 20:40", "sentiment": "negative", "sentiment_pct": 41, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "X4 Pharmaceuticals appoints Kelly Gold to board of directors By Investing.com", "summary": "X4 Pharmaceuticals has appointed Kelly Gold to its board of directors, effective immediately. Gold, who is currently the CFO of CAMP4 Therapeutics, will also serve on the audit committee. Her appointment comes as X4 Pharmaceuticals continues to advance its therapies for rare hema", "url": "https://ca.investing.com/news/stock-market-news/x4-pharmaceuticals-appoints-kelly-gold-to-board-of-directors-93CH-4715802", "source_name": "Investing.com Canada", "published_at": "2026-07-01T11:39:51", "published_display": "01 Jul 2026 11:39", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "X4 Pharmaceuticals adds CAMP4 CFO Kelly Gold to its board", "summary": "X4 Pharmaceuticals (Nasdaq: XFOR) has appointed Kelly Gold, the current Chief Financial Officer at CAMP4 Therapeutics, to its Board of Directors, effective July 1, 2026. Ms. Gold will serve as an independent director and a member of the Audit Committee, bringing significant finan", "url": "https://www.stocktitan.net/news/XFOR/x4-pharmaceuticals-appoints-kelly-gold-experienced-chief-financial-xs6mf91xkqya.html", "source_name": "Stock Titan", "published_at": "2026-07-01T10:39:51", "published_display": "01 Jul 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "X4 Pharmaceuticals, Inc.(NasdaqCM: XFOR) added to Russell 2000 Index", "summary": "X4 Pharmaceuticals, Inc. (NasdaqCM: XFOR), a biopharmaceutical company specializing in rare immune-related diseases, has been included in the Russell 2000 Index. The article also notes its addition to other Russell indexes, including the Russell 2000 Value Benchmark, Russell Micr", "url": "https://www.marketscreener.com/news/x4-pharmaceuticals-inc-nasdaqcm-xfor-added-to-russell-2000-index-ce7f5fdfda8cf124", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T18:51:00", "published_display": "29 Jun 2026 18:51", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "X4 Pharmaceuticals, Inc.(NasdaqCM: XFOR) added to Russell Microcap Index", "summary": "X4 Pharmaceuticals, Inc. (NasdaqCM: XFOR) has been added to the Russell Microcap Index. This inclusion follows an earlier announcement that the company was also added to the Russell 3000E Index. X4 Pharmaceuticals is a commercial-stage biopharmaceutical company focused on develop", "url": "https://www.marketscreener.com/news/x4-pharmaceuticals-inc-nasdaqcm-xfor-added-to-russell-microcap-index-ce7f5fdeda80f025", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T05:39:58", "published_display": "29 Jun 2026 05:39", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "X4 Pharmaceuticals updates investor plans, shares remain thinly traded on Nasdaq", "summary": "X4 Pharmaceuticals (XFOR) is updating investors on its clinical pipeline and funding strategy, particularly for its lead candidate mavorixafor targeting rare diseases linked to CXCR4 pathway dysfunction. Despite outlining key milestones and potential strategic options, the compan", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/x4-pharmaceuticals-updates-investor-plans-shares-remain-thinly-traded-on/69633600", "source_name": "Ad-hoc-news.de", "published_at": "2026-06-26T13:09:44", "published_display": "26 Jun 2026 13:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "48Q0 Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for X4 Pharmaceuticals, Inc. (48Q0) on the Frankfurt Stock Exchange, based on analyst opinions. It details historical price data, earnings reports, revenue figures, net income, and other financial metrics for the company. The repo", "url": "https://www.tradingview.com/symbols/FWB-48Q0/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T07:09:44", "published_display": "26 Jun 2026 07:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "X4 Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:XFOR)", "summary": "This article provides financial actuals and estimates for X4 Pharmaceuticals, Inc. (NASDAQ:XFOR), including its current stock price, market capitalization, earnings, and revenue. It also covers analyst forecasts, historical price movements, volatility, and details on upcoming ear", "url": "https://www.tradingview.com/symbols/NASDAQ-XFOR/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T06:10:59", "published_display": "26 Jun 2026 06:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "X4 Pharmaceuticals, Thursday trading bias in shares", "summary": "X4 Pharmaceuticals (XFOR) is listed on NASDAQ, and its shares traded based on a broad market tone on Thursday, June 25, 2026. The stock's performance is contextualized by larger U.S. growth names and the day's risk appetite, with Micron dominating early market coverage. The compa", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/x4-pharmaceuticals-thursday-trading-bias-in-shares/69623503", "source_name": "Ad-hoc-news.de", "published_at": "2026-06-25T11:41:03", "published_display": "25 Jun 2026 11:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "X4 Pharmaceuticals Inc (XFOR) Institutional Confidence", "summary": "X4 Pharmaceuticals Inc (XFOR) currently holds an institutional shareholding score of 3.00, placing it 94th out of 157 in the Pharmaceuticals industry. The institutional shareholding proportion is 9.67%, marking an 89.43% decrease quarter-over-quarter. Bill Nygren from OAKMX is no", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-xfor/sentiment", "source_name": "TradingKey", "published_at": "2026-06-19T03:10:33", "published_display": "19 Jun 2026 03:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "X4 Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/x4-pharmaceuticals-present-2026-jefferies-110000553.html", "source_name": "GlobeNewswire", "published_at": "2026-05-27T11:00:00+00:00", "published_display": "27 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bears are Losing Control Over X4 Pharmaceuticals (XFOR), Here's Why It's a 'Buy' Now", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/bears-losing-control-over-x4-135502538.html", "source_name": "Zacks", "published_at": "2026-05-20T13:55:02+00:00", "published_display": "20 May 2026 13:55", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The X4 Pharmaceuticals (XFOR) Story Is Shifting With Mavorixafor And New EU Progress", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNLUdKRGY5clJXMldwcTFORjRwbC1fdXY4Q1d1M0tqaTVzUEl1c0NmeVhpak5DZk5LeVAza2FwQU9IbmlpclFlYmpXS1dxb284R3R2ZVNvTEI0aWl3T2w0S0tuRGVsNHRlZXVzNndZTHR0UWMyT0FDXzBRTXdTTHoxZ1g3QlZtUGN3UUdsc2hJdC1iSlFFSENfOTZiSDl1WWNVR0VfakxB?oc=5", "source_name": "Market source", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "X4 Pharmaceuticals (XFOR) Upgraded to Buy: Here's What You Should Know", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxOYV95Zm94aE5lOVllS3BiTThrVXlQSERNZTktaHVaT0F1cGFCMDZHb2J6TEtJOVFpc0lBa00zbjVaWF9pT0hpckMzajZvemJzSHFEMkVLTUREM1dYRXRjd1VOenBhQ2ZZd2hBcVhESzRaS0c4NEdETEYzblVrbUVMdE1zV2ppTUtYLUs1NFVJMTdLNDZJUnZOZHRyNlJ3YWdhY2Nv?oc=5", "source_name": "Market source", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This Insider Has Just Sold Shares In X4 Pharmaceuticals", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Here is Why X4 Pharmaceuticals (XFOR) is Among the Unrivaled Penny Stocks to Buy Now", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxQM2Z5Z3VFd3VzUThTV2RUWlZzMzJtMFpsYWQzMWdSQy1Qa1psZldxVzJrODZOeVNxMjBudjA1WlZQM3I1RjEtY3FJajc3RU5hcE9WVm5qOEFZbkdxaG9zZDJTQ3did3BCeUtRVDVMMEJfNUlGdExmc1pUZ2VLdklZRVQyaGdMaDNjNGtTR21zeFdhdmh0RWc5dV94WUx3Q1k?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "X4 Pharmaceuticals (XFOR) CFO sells shares to cover tax obligation", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxORUVVUHV3X1VpZW1tem5yWWVRZk50SlF2UUY4WXdDaVVtazl0QUNTYkpKa0NqbmFhdEVaRC04MjZ3ZlljcGZvQ3YxaWJiT1lLNzd0ZDcxU0FxUFp5Vkl3NkZqa1gyVkM0dmxDeGNfMzhIamVjX2otWndOdXlzVnFNbENyYmt2MGF3dk1zblZIa25BX21fNkdwNXU5TEEzbThIWHFZMmtQc1d6MThMcFFrRF9NcGI2ZVE?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] X4 Pharmaceuticals, Inc SEC Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxNZm85ZHZkT1lHSDNzYTMtVE1vM0RLRHNFZl8tUVNzNVlTZEJXVl9YdkRzUHgtdVZfSUZlbWowMUI1R2w0OVlBODJ1SVdmdWxHVThOUGdaQUpGMS1OdzNLdS1CSnJjY0pTQkxjeVFJLVQ1ODQ2bmhPSmJWZUg5U3ZlUkhIZ1RLWVlTVmpyMFdKb3A4dk5TQ05CZ01YRjNGc2pX?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "X4 Pharmaceuticals: Q1 Earnings Snapshot", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/x4-pharmaceuticals-q1-earnings-snapshot-112659453.html", "source_name": "Associated Press", "published_at": "2026-05-06T11:26:59+00:00", "published_display": "06 May 2026 11:26", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "X4 Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9gFBVV95cUxNUFppR1U5b2xmRWZfYVlKSEUxUHBZSGRHdXp3cjBhenJibHFMR0lTaHlXVWJOTkpiclBqMElsMm1ab3JjZlpidEw4N1NUeWV1RmVwbWZWcGRGWkxzVDlCYUd4djhkbVJRWmc0cDB5aDM3eHZLSHRfOFcwQ1d3dW5CX1pyS1BialhtbHF1RTJUeG04NXBJWHVUd0MtMEVNVm5Ycnpmd0p0MEtDbTdzd25yRnNZQ0Z2Ykd2LTM0SWliOHowTE13SHhfYlduWnZMTTZwZnZOdWVjYk85cHJEWHlDcnlVV1lPQ0RvNlk2YzVrMEdvaU9SS3c?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "X4 Pharmaceuticals (XFOR) Reports Q1 Loss, Lags Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxPOUNmN19ib0NpaTZ5Q3dpT1RXanpVQUFxb2JrNlZPT0VlZTlZdm5YLXBJcWx4eEJxSXhjNWFMRkJOU05fYlNBTlA4bGNVdFV4UXItaGlTVGxHR1Ezenl5RndxNGtxSlVQTUVXQ2g2RmxONFAyZEstMU5jeGlVMzV0ckRtaXdBcWU2a2NZX1dyVC1oaWZLbHZHelVGS1Q3Qms3?oc=5", "source_name": "Market source", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "X4 Pharmaceuticals, Inc. Common Stock (XFOR) Stock Price Today & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiV0FVX3lxTE8zeTFDODdXcDY4M053ZkZyYUgxY2NJVEctZEoxcVpuYWw1TmxlVEN0RXVjZVQ4LUpBcTNTVUE2SHY1ODIwMXlaV1hyRGw5Vm5YSGNHT2pPSQ?oc=5", "source_name": "Gotrade", "published_at": "2026-01-09T21:26:20+00:00", "published_display": "09 Jan 2026 21:26", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "X4 Pharmaceuticals Announces $60 Million Equity Financing", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgJBVV95cUxQbnlrVVhsMTN1VUR4cFVTY3pEeWs0YTdWZlExRVRDWTBCUVBQQmZEWElrcWQtaDlFZ3VmenlMeGcxOXpjVW5DNTlPWW9FOHZTa2Q5elVxa1ZTWnJBQWg5Ny04ckxtcWMyamRqbnlldHFDTXp4M1hDb1UyNVc2dGJmeVJvbjJacGd5cHZORGFfc3BWZHpzOXlVQVJhWHgyeUtqNFVTU2NYWUdzSXBNYjlRcWZmcElmTkRFUjJERkluTll2Wk96em5IeEhHOE9EdkdrNkE2V3o2bzJ4X21WM2VLTmJIel9kSl94Vi1SSjFzTzNSVjdUMWNnQkpkUUxNUWVqd1l5RXBSWUNqZUxSNzBKczRJQml4UQ?oc=5", "source_name": "GlobeNewswire", "published_at": "2025-08-12T07:00:00+00:00", "published_display": "12 Aug 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XFOR SEC Filings - X4 Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms", "summary": "", "url": "https://news.google.com/rss/articles/CBMiV0FVX3lxTFBQRlVKcjlrUENjRFhzYjk5M3BNeFNSNHJiUzFEdkJuR1F3TnVpRGdneTRLU2VjcXJKeko2d3FYM3dUc0FTRUpqMl9IR2plRVZWakMtdk9ycw?oc=5", "source_name": "Stock Titan", "published_at": "2025-06-29T02:16:21+00:00", "published_display": "29 Jun 2025 02:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "X4 Pharmaceuticals (XFOR) Stock Price, News & Analysis $XFOR", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE4tYVlxZHUwUjF2UW9XcDFPbld2T2paTkd6V1JyaVBNM2N5M3VoNU1wTzgzczFlNTh5TVROcHFIdUpvMHhVdDdESzc0QWlXRWtQOWJQSGZwR1FIUQ?oc=5", "source_name": "MarketBeat", "published_at": "2019-05-22T00:14:45+00:00", "published_display": "22 May 2019 00:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "X4 Pharmaceuticals (XFOR) Proxy filing Summary", "summary": "X4 Pharmaceuticals has released a proxy filing summary detailing the upcoming annual meeting on May 11, 2026. Stockholders will vote on director elections, auditor ratification, an equity plan amendment, and executive compensation. The Board recommends approving all proposals, an", "url": "https://quartr.com/events/x4-pharmaceuticals-xfor-proxy-filing_onpZyYpT", "source_name": "Quartr", "published_at": "2026-07-13T14:41:18", "published_display": "13 Jul 2026 14:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "X4 Pharmaceuticals (XFOR) Q4 2025 earnings summary", "summary": "X4 Pharmaceuticals (XFOR) reported its Q4 2025 earnings, highlighting that enrollment for its 4WARD Phase 3 chronic neutropenia trial is on track for completion in Q3 2026 and expects final EU approval for mavorixafor for WHIM syndrome in Q2 2026. The company posted net product s", "url": "https://quartr.com/events/x4-pharmaceuticals-inc-xfor-q4-2025_onpZBAiR", "source_name": "Quartr", "published_at": "2026-07-13T13:12:21", "published_display": "13 Jul 2026 13:12", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "X4 Pharmaceuticals (XFOR) Corporate presentation Summary", "summary": "X4 Pharmaceuticals is focused on developing mavorixafor for chronic neutropenia, with its Phase 3 4WARD study fully enrolling by Q3 2026. The company secured $240M, reduced its workforce by 50%, and expects its cash runway to last through 2028. Mavorixafor, already approved for W", "url": "https://quartr.com/events/x4-pharmaceuticals-inc-xfor-corporate-presentation_onpZys2t", "source_name": "Quartr", "published_at": "2026-07-13T00:41:18", "published_display": "13 Jul 2026 00:41", "sentiment": "positive", "sentiment_pct": 77, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "X4 Pharmaceuticals (XFOR) Registration filing Summary", "summary": "X4 Pharmaceuticals (XFOR) has filed a registration summary, detailing its focus on developing therapeutics for rare hematology diseases, primarily with its main asset, mavorixafor. The company provided financial metrics as of March 31, 2026, including outstanding shares and per-s", "url": "https://quartr.com/events/x4-pharmaceuticals-inc-xfor-registration-filing_onpZy5um", "source_name": "Quartr", "published_at": "2026-07-13T00:41:18", "published_display": "13 Jul 2026 00:41", "sentiment": "positive", "sentiment_pct": 59, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "X4 Pharmaceuticals (XFOR) Q1 2026 earnings summary", "summary": "X4 Pharmaceuticals reported a Q1 2026 net loss of $20.2 million, a significant drop from Q1 2025's net income, primarily due to lower license revenue despite increased product revenue from XOLREMDI. The company is focused on commercializing XOLREMDI, recently approved in the EU, ", "url": "https://quartr.com/events/x4-pharmaceuticals-inc-xfor-q1-2026_onpZyscr", "source_name": "Quartr", "published_at": "2026-07-13T00:41:18", "published_display": "13 Jul 2026 00:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wells Fargo initiates X4 Pharmaceuticals stock coverage with overweight rating by Investing.com", "summary": "Wells Fargo has initiated coverage on X4 Pharmaceuticals (NASDAQ:XFOR) with an overweight rating and an $11.00 price target, citing the potential of its drug candidate mavorixafor for chronic neutropenia. A Phase 3 trial readout is anticipated in the second half of 2027, with the", "url": "https://ca.investing.com/news/stock-market-news/wells-fargo-initiates-x4-pharmaceuticals-stock-coverage-with-overweight-rating-93CH-4728859", "source_name": "Investing.com Canada", "published_at": "2026-07-10T10:39:45", "published_display": "10 Jul 2026 10:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "X4 Pharmaceuticals stock focuses on rare disease pipeline after Nasdaq listing", "summary": "X4 Pharmaceuticals, trading on Nasdaq as XFOR, is a clinical-stage biopharmaceutical company focused on developing small-molecule therapies for rare primary immunodeficiency and related disorders. Its strategy centers on niche medical needs and orphan drug designation, providing ", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/x4-pharmaceuticals-stock-focuses-on-rare-disease-pipeline-after-nasdaq/69733172", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-09T15:07:04", "published_display": "09 Jul 2026 15:07", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "X4 Pharmaceuticals gives new employees 750,000 stock options", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQbFBSMGtSMUlTYWVKQktEWVEydGVyMXNZak1FRHNSSFlKRGZCbU9lUGZMWVQzemJCNFZNSTVBamJLQzNjX29RM09aLTlGbHFTNmhENDBBMEIwNWFId2lYbk83V1Nsc0RFYWFKWDhyaU5jX2JiSzlBZFVoSHJQVGRYRXVNRWlkdkhwNm1HQ3p2cTJhUlc0Nk8xb1JsNGN4NGVPN1llaDI4alJkbm9ObG85bS01Rk1YZWRQTUtjN1VTZw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-07T20:30:00+00:00", "published_display": "07 Jul 2026 20:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "summary": "X4 Pharmaceuticals (Nasdaq: XFOR) has granted 750,000 stock options to new employees as inducement awards under its 2019 Inducement Equity Incentive Plan, effective July 6, 2026. The options have an exercise price of $4.03 per share, matching the closing price on the grant date, ", "url": "https://www.stocktitan.net/news/XFOR/x4-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-971eku1v7qwh.html", "source_name": "Stock Titan", "published_at": "2026-07-07T20:10:01", "published_display": "07 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of X4 Pharmaceuticals, Inc. \u2013 NASDAQ:XFOR", "summary": "This article provides the \"Price to earnings forward\" metric for X4 Pharmaceuticals, Inc. (NASDAQ: XFOR). The information, sourced from TradingView and FactSet, is presented without specific numerical values but indicates the availability of financial data for the company. The co", "url": "https://www.tradingview.com/symbols/NASDAQ-XFOR/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T12:40:01", "published_display": "06 Jul 2026 12:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XFOR Stock News Today | Earnings, Events & Price Alerts", "summary": "This article provides recent news and event updates for X4 Pharmaceuticals (XFOR). Key highlights include recent grants of inducement awards to new employees, the appointment of Kelly Gold to the Board of Directors, and the completion of EU approval for XOLREMDI\u00ae, along with posi", "url": "https://intellectia.ai/en/stock/XFOR/news", "source_name": "Intellectia AI", "published_at": "2026-07-06T11:11:03", "published_display": "06 Jul 2026 11:11", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of X4 Pharmaceuticals, Inc. \u2013 NASDAQ:XFOR", "summary": "This article focuses on the \"Price to sales forward\" financial metric for X4 Pharmaceuticals, Inc. (NASDAQ: XFOR). It appears to be a stub or a section within a larger financial data platform, providing a snapshot of this specific valuation ratio for the company without further d", "url": "https://www.tradingview.com/symbols/NASDAQ-XFOR/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T02:09:33", "published_display": "05 Jul 2026 02:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of X4 Pharmaceuticals, Inc. \u2013 NASDAQ:XFOR", "summary": "This article focuses on the enterprise value to EBITDA forward for X4 Pharmaceuticals, Inc. (NASDAQ: XFOR). The content, likely financial data, is presented through TradingView, a financial platform. It indicates that the market is closed and no trades have occurred for the speci", "url": "https://www.tradingview.com/symbols/NASDAQ-XFOR/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-03T11:10:30", "published_display": "03 Jul 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "X4 Pharmaceuticals Appoints Kelly Gold, Experienced Chief Financial Officer, to its Board of Directors", "summary": "X4 Pharmaceuticals (Nasdaq: XFOR) has appointed Kelly Gold, an experienced Chief Financial Officer, to its Board of Directors, effective July 1, 2026. Ms. Gold brings significant financial leadership and capital markets expertise, and will serve as an independent director and mem", "url": "https://www.sahmcapital.com/news/content/x4-pharmaceuticals-appoints-kelly-gold-experienced-chief-financial-officer-to-its-board-of-directors-2026-07-01", "source_name": "Sahm", "published_at": "2026-07-02T22:40:01", "published_display": "02 Jul 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kelly Gold joins X4 Pharmaceuticals (Nasdaq: XFOR) board and Audit Committee", "summary": "X4 Pharmaceuticals (Nasdaq: XFOR) has appointed Kelly Gold as a Class II independent director to its Board, effective July 1, 2026. This appointment expands the board from five to six members, and Gold will also serve on the Audit Committee. Gold brings extensive financial leader", "url": "https://www.stocktitan.net/sec-filings/XFOR/8-k-x4-pharmaceuticals-inc-reports-material-event-f7da0be9f79e.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:40:40", "published_display": "01 Jul 2026 20:40", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "X4 Pharmaceuticals (XFOR) director Gold Kelly files initial Form 3 ownership", "summary": "X4 Pharmaceuticals director Gold Kelly has filed an initial Form 3, indicating her beneficial ownership status as a director. This filing serves as a baseline disclosure and does not report any insider stock transactions or derivative securities. The Form 3 details Kelly's positi", "url": "https://www.stocktitan.net/sec-filings/XFOR/form-3-x4-pharmaceuticals-inc-initial-statement-of-beneficial-ownersh-0433155755f8.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:40:40", "published_display": "01 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 X4 Pharmaceuticals Inc For: 1 July By Investing.com", "summary": "This article from Investing.com reports the filing of Form 4 for X4 Pharmaceuticals Inc., dated July 1st. Form 4 is a document that must be filed with the SEC whenever a company insider (such as an officer, director, or 10%+ shareholder) trades the company's stock. The article pr", "url": "https://ca.investing.com/news/stock-market-news/form-4-x4-pharmaceuticals-inc-for-1-july-93CH-4717027", "source_name": "Investing.com Canada", "published_at": "2026-07-01T20:40:40", "published_display": "01 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director Kelly Gold granted 110,000 X4 Pharmaceuticals (XFOR) stock options at $4.085", "summary": "X4 Pharmaceuticals director Kelly Gold was granted 110,000 stock options with an exercise price of $4.085 per share, expiring on July 1, 2036. These options vest fully on the one-year anniversary of the grant date, provided Gold continues to provide services to the company. Follo", "url": "https://www.stocktitan.net/sec-filings/XFOR/form-4-x4-pharmaceuticals-inc-insider-trading-activity-58ca91bac4e3.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:40:40", "published_display": "01 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "X4 Pharmaceuticals (XFOR) CFO sells 8,543 shares to cover RSU tax", "summary": "X4 Pharmaceuticals' CFO, David Kirske, sold 8,543 shares of common stock at a weighted average price of $4.2641 per share. This sale was conducted to satisfy a personal income tax obligation arising from the settlement of a restricted stock unit (RSU) award. Following the transac", "url": "https://www.stocktitan.net/sec-filings/XFOR/form-4-x4-pharmaceuticals-inc-insider-trading-activity-35222244f043.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:40:40", "published_display": "01 Jul 2026 20:40", "sentiment": "negative", "sentiment_pct": 41, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "X4 Pharmaceuticals appoints Kelly Gold to board of directors By Investing.com", "summary": "X4 Pharmaceuticals has appointed Kelly Gold to its board of directors, effective immediately. Gold, who is currently the CFO of CAMP4 Therapeutics, will also serve on the audit committee. Her appointment comes as X4 Pharmaceuticals continues to advance its therapies for rare hema", "url": "https://ca.investing.com/news/stock-market-news/x4-pharmaceuticals-appoints-kelly-gold-to-board-of-directors-93CH-4715802", "source_name": "Investing.com Canada", "published_at": "2026-07-01T11:39:51", "published_display": "01 Jul 2026 11:39", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "X4 Pharmaceuticals adds CAMP4 CFO Kelly Gold to its board", "summary": "X4 Pharmaceuticals (Nasdaq: XFOR) has appointed Kelly Gold, the current Chief Financial Officer at CAMP4 Therapeutics, to its Board of Directors, effective July 1, 2026. Ms. Gold will serve as an independent director and a member of the Audit Committee, bringing significant finan", "url": "https://www.stocktitan.net/news/XFOR/x4-pharmaceuticals-appoints-kelly-gold-experienced-chief-financial-xs6mf91xkqya.html", "source_name": "Stock Titan", "published_at": "2026-07-01T10:39:51", "published_display": "01 Jul 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "X4 Pharmaceuticals, Inc.(NasdaqCM: XFOR) added to Russell 2000 Index", "summary": "X4 Pharmaceuticals, Inc. (NasdaqCM: XFOR), a biopharmaceutical company specializing in rare immune-related diseases, has been included in the Russell 2000 Index. The article also notes its addition to other Russell indexes, including the Russell 2000 Value Benchmark, Russell Micr", "url": "https://www.marketscreener.com/news/x4-pharmaceuticals-inc-nasdaqcm-xfor-added-to-russell-2000-index-ce7f5fdfda8cf124", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T18:51:00", "published_display": "29 Jun 2026 18:51", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "X4 Pharmaceuticals, Inc.(NasdaqCM: XFOR) added to Russell Microcap Index", "summary": "X4 Pharmaceuticals, Inc. (NasdaqCM: XFOR) has been added to the Russell Microcap Index. This inclusion follows an earlier announcement that the company was also added to the Russell 3000E Index. X4 Pharmaceuticals is a commercial-stage biopharmaceutical company focused on develop", "url": "https://www.marketscreener.com/news/x4-pharmaceuticals-inc-nasdaqcm-xfor-added-to-russell-microcap-index-ce7f5fdeda80f025", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T05:39:58", "published_display": "29 Jun 2026 05:39", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "X4 Pharmaceuticals updates investor plans, shares remain thinly traded on Nasdaq", "summary": "X4 Pharmaceuticals (XFOR) is updating investors on its clinical pipeline and funding strategy, particularly for its lead candidate mavorixafor targeting rare diseases linked to CXCR4 pathway dysfunction. Despite outlining key milestones and potential strategic options, the compan", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/x4-pharmaceuticals-updates-investor-plans-shares-remain-thinly-traded-on/69633600", "source_name": "Ad-hoc-news.de", "published_at": "2026-06-26T13:09:44", "published_display": "26 Jun 2026 13:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "48Q0 Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for X4 Pharmaceuticals, Inc. (48Q0) on the Frankfurt Stock Exchange, based on analyst opinions. It details historical price data, earnings reports, revenue figures, net income, and other financial metrics for the company. The repo", "url": "https://www.tradingview.com/symbols/FWB-48Q0/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T07:09:44", "published_display": "26 Jun 2026 07:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "X4 Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:XFOR)", "summary": "This article provides financial actuals and estimates for X4 Pharmaceuticals, Inc. (NASDAQ:XFOR), including its current stock price, market capitalization, earnings, and revenue. It also covers analyst forecasts, historical price movements, volatility, and details on upcoming ear", "url": "https://www.tradingview.com/symbols/NASDAQ-XFOR/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T06:10:59", "published_display": "26 Jun 2026 06:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "X4 Pharmaceuticals, Thursday trading bias in shares", "summary": "X4 Pharmaceuticals (XFOR) is listed on NASDAQ, and its shares traded based on a broad market tone on Thursday, June 25, 2026. The stock's performance is contextualized by larger U.S. growth names and the day's risk appetite, with Micron dominating early market coverage. The compa", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/x4-pharmaceuticals-thursday-trading-bias-in-shares/69623503", "source_name": "Ad-hoc-news.de", "published_at": "2026-06-25T11:41:03", "published_display": "25 Jun 2026 11:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "X4 Pharmaceuticals Inc (XFOR) Institutional Confidence", "summary": "X4 Pharmaceuticals Inc (XFOR) currently holds an institutional shareholding score of 3.00, placing it 94th out of 157 in the Pharmaceuticals industry. The institutional shareholding proportion is 9.67%, marking an 89.43% decrease quarter-over-quarter. Bill Nygren from OAKMX is no", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-xfor/sentiment", "source_name": "TradingKey", "published_at": "2026-06-19T03:10:33", "published_display": "19 Jun 2026 03:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "X4 Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/x4-pharmaceuticals-present-2026-jefferies-110000553.html", "source_name": "GlobeNewswire", "published_at": "2026-05-27T11:00:00+00:00", "published_display": "27 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bears are Losing Control Over X4 Pharmaceuticals (XFOR), Here's Why It's a 'Buy' Now", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/bears-losing-control-over-x4-135502538.html", "source_name": "Zacks", "published_at": "2026-05-20T13:55:02+00:00", "published_display": "20 May 2026 13:55", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The X4 Pharmaceuticals (XFOR) Story Is Shifting With Mavorixafor And New EU Progress", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNLUdKRGY5clJXMldwcTFORjRwbC1fdXY4Q1d1M0tqaTVzUEl1c0NmeVhpak5DZk5LeVAza2FwQU9IbmlpclFlYmpXS1dxb284R3R2ZVNvTEI0aWl3T2w0S0tuRGVsNHRlZXVzNndZTHR0UWMyT0FDXzBRTXdTTHoxZ1g3QlZtUGN3UUdsc2hJdC1iSlFFSENfOTZiSDl1WWNVR0VfakxB?oc=5", "source_name": "Market source", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "X4 Pharmaceuticals (XFOR) Upgraded to Buy: Here's What You Should Know", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxOYV95Zm94aE5lOVllS3BiTThrVXlQSERNZTktaHVaT0F1cGFCMDZHb2J6TEtJOVFpc0lBa00zbjVaWF9pT0hpckMzajZvemJzSHFEMkVLTUREM1dYRXRjd1VOenBhQ2ZZd2hBcVhESzRaS0c4NEdETEYzblVrbUVMdE1zV2ppTUtYLUs1NFVJMTdLNDZJUnZOZHRyNlJ3YWdhY2Nv?oc=5", "source_name": "Market source", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This Insider Has Just Sold Shares In X4 Pharmaceuticals", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here is Why X4 Pharmaceuticals (XFOR) is Among the Unrivaled Penny Stocks to Buy Now", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxQM2Z5Z3VFd3VzUThTV2RUWlZzMzJtMFpsYWQzMWdSQy1Qa1psZldxVzJrODZOeVNxMjBudjA1WlZQM3I1RjEtY3FJajc3RU5hcE9WVm5qOEFZbkdxaG9zZDJTQ3did3BCeUtRVDVMMEJfNUlGdExmc1pUZ2VLdklZRVQyaGdMaDNjNGtTR21zeFdhdmh0RWc5dV94WUx3Q1k?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "X4 Pharmaceuticals (XFOR) CFO sells shares to cover tax obligation", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxORUVVUHV3X1VpZW1tem5yWWVRZk50SlF2UUY4WXdDaVVtazl0QUNTYkpKa0NqbmFhdEVaRC04MjZ3ZlljcGZvQ3YxaWJiT1lLNzd0ZDcxU0FxUFp5Vkl3NkZqa1gyVkM0dmxDeGNfMzhIamVjX2otWndOdXlzVnFNbENyYmt2MGF3dk1zblZIa25BX21fNkdwNXU5TEEzbThIWHFZMmtQc1d6MThMcFFrRF9NcGI2ZVE?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] X4 Pharmaceuticals, Inc SEC Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxNZm85ZHZkT1lHSDNzYTMtVE1vM0RLRHNFZl8tUVNzNVlTZEJXVl9YdkRzUHgtdVZfSUZlbWowMUI1R2w0OVlBODJ1SVdmdWxHVThOUGdaQUpGMS1OdzNLdS1CSnJjY0pTQkxjeVFJLVQ1ODQ2bmhPSmJWZUg5U3ZlUkhIZ1RLWVlTVmpyMFdKb3A4dk5TQ05CZ01YRjNGc2pX?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "X4 Pharmaceuticals: Q1 Earnings Snapshot", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/x4-pharmaceuticals-q1-earnings-snapshot-112659453.html", "source_name": "Associated Press", "published_at": "2026-05-06T11:26:59+00:00", "published_display": "06 May 2026 11:26", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "X4 Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9gFBVV95cUxNUFppR1U5b2xmRWZfYVlKSEUxUHBZSGRHdXp3cjBhenJibHFMR0lTaHlXVWJOTkpiclBqMElsMm1ab3JjZlpidEw4N1NUeWV1RmVwbWZWcGRGWkxzVDlCYUd4djhkbVJRWmc0cDB5aDM3eHZLSHRfOFcwQ1d3dW5CX1pyS1BialhtbHF1RTJUeG04NXBJWHVUd0MtMEVNVm5Ycnpmd0p0MEtDbTdzd25yRnNZQ0Z2Ykd2LTM0SWliOHowTE13SHhfYlduWnZMTTZwZnZOdWVjYk85cHJEWHlDcnlVV1lPQ0RvNlk2YzVrMEdvaU9SS3c?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "X4 Pharmaceuticals (XFOR) Reports Q1 Loss, Lags Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxPOUNmN19ib0NpaTZ5Q3dpT1RXanpVQUFxb2JrNlZPT0VlZTlZdm5YLXBJcWx4eEJxSXhjNWFMRkJOU05fYlNBTlA4bGNVdFV4UXItaGlTVGxHR1Ezenl5RndxNGtxSlVQTUVXQ2g2RmxONFAyZEstMU5jeGlVMzV0ckRtaXdBcWU2a2NZX1dyVC1oaWZLbHZHelVGS1Q3Qms3?oc=5", "source_name": "Market source", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "X4 Pharmaceuticals, Inc. Common Stock (XFOR) Stock Price Today & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiV0FVX3lxTE8zeTFDODdXcDY4M053ZkZyYUgxY2NJVEctZEoxcVpuYWw1TmxlVEN0RXVjZVQ4LUpBcTNTVUE2SHY1ODIwMXlaV1hyRGw5Vm5YSGNHT2pPSQ?oc=5", "source_name": "Gotrade", "published_at": "2026-01-09T21:26:20+00:00", "published_display": "09 Jan 2026 21:26", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "X4 Pharmaceuticals Announces $60 Million Equity Financing", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgJBVV95cUxQbnlrVVhsMTN1VUR4cFVTY3pEeWs0YTdWZlExRVRDWTBCUVBQQmZEWElrcWQtaDlFZ3VmenlMeGcxOXpjVW5DNTlPWW9FOHZTa2Q5elVxa1ZTWnJBQWg5Ny04ckxtcWMyamRqbnlldHFDTXp4M1hDb1UyNVc2dGJmeVJvbjJacGd5cHZORGFfc3BWZHpzOXlVQVJhWHgyeUtqNFVTU2NYWUdzSXBNYjlRcWZmcElmTkRFUjJERkluTll2Wk96em5IeEhHOE9EdkdrNkE2V3o2bzJ4X21WM2VLTmJIel9kSl94Vi1SSjFzTzNSVjdUMWNnQkpkUUxNUWVqd1l5RXBSWUNqZUxSNzBKczRJQml4UQ?oc=5", "source_name": "GlobeNewswire", "published_at": "2025-08-12T07:00:00+00:00", "published_display": "12 Aug 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XFOR SEC Filings - X4 Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms", "summary": "", "url": "https://news.google.com/rss/articles/CBMiV0FVX3lxTFBQRlVKcjlrUENjRFhzYjk5M3BNeFNSNHJiUzFEdkJuR1F3TnVpRGdneTRLU2VjcXJKeko2d3FYM3dUc0FTRUpqMl9IR2plRVZWakMtdk9ycw?oc=5", "source_name": "Stock Titan", "published_at": "2025-06-29T02:16:21+00:00", "published_display": "29 Jun 2025 02:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "X4 Pharmaceuticals (XFOR) Stock Price, News & Analysis $XFOR", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE4tYVlxZHUwUjF2UW9XcDFPbld2T2paTkd6V1JyaVBNM2N5M3VoNU1wTzgzczFlNTh5TVROcHFIdUpvMHhVdDdESzc0QWlXRWtQOWJQSGZwR1FIUQ?oc=5", "source_name": "MarketBeat", "published_at": "2019-05-22T00:14:45+00:00", "published_display": "22 May 2019 00:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 89, "total_relevant": 51, "sentiment_summary": {"positive": 14, "negative": 3, "neutral": 34, "score": 55, "total": 51, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 82, "events": [{"event": "general", "label": "Market update", "weight": 17.4, "count": 31}, {"event": "earnings", "label": "Earnings", "weight": 8.6, "count": 17}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 14, "negative_events": 3}, "market_context": {"has_market_context": true, "latest_close": 4.41, "latest_week": "2026-07-10", "one_week_move": 6.8, "four_week_move": 10.3, "twelve_week_move": 2.8, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.170917, "market_dynamics_buy_signal": false, "relative_strength": 4.693657, "fair_value_gap": -72.0, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 31.7335, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+6.8% over one week, +10.3% over four weeks, trend active, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 65, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 10}, {"label": "Market source", "count": 9}, {"label": "TradingView", "count": 6}, {"label": "Quartr", "count": 5}, {"label": "Investing.com Canada", "count": 3}, {"label": "Ad-hoc-news.de", "count": 3}, {"label": "GlobeNewswire", "count": 3}, {"label": "simplywall.st", "count": 3}], "tiers": [{"label": "Direct company coverage", "count": 43}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 31}, {"label": "Earnings", "count": 17}, {"label": "Analyst action", "count": 2}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "55/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "82/100 classification confidence."}, {"label": "Company focus", "value": "43", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+6.8% over one week, +10.3% over four weeks, trend active, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "X4 Pharmaceuticals (XFOR) Proxy filing Summary"}], "updated_at": "2026-07-16T11:42:45.173199+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}